



Influenza Work Group—Introduction

Dr. Jamie Loehr (Work Group Chair)

Advisory Committee on Immunization Practices

October 25, 2023

Influenza Work Group

ACIP Members

- Jamie Loehr (Chair)
- Keipp Talbot
- Camille Kotton

Ex Officio

- Timothy Brennan (FDA)
- Uzo Chukwuma (IHS)
- Jeffrey Kelman (CMS)
- Valerie Marshall (OASH)
- Cynthia Nolletti (FDA)
- Chris Roberts (NIH)

Liaison Representatives and Consultants

- Robert Atmar
- Kevin Ault
- Ed Belongia
- Hank Bernstein
- Thomas Boyce
- Kris Bryant
- Doug Campos-Outcalt
- Sarah Coles
- Frances Ferguson
- Alicia Fry
- Sandra Fryhofer
- Wendy Keitel
- Marie-Michèle Léger
- Susan Lett
- Krissy Moehling

- Zackary Moore
- Rebecca Morgan
- Kathy Neuzil
- Jesse Papenburg
- William Schaffner
- Rob Schechter
- Ken Schmader
- Tamara Sheffield
- Angela Sinilaite
- Patsy Stinchfield
- Peter Szilagyi
- Matthew Zahn

CDC Lead

- Lisa Grohskopf

CDC Participants

- Lenee Blanton
- Karen Broder
- Alicia Budd
- Jessie Chung
- Sascha Ellington
- Jill Ferdinands
- Brendan Flannery
- Andrew Kroger
- Samantha Olson
- David Shay
- Tom Shimabukuro
- Mark Tenforde
- Tim Uyeki

Influenza Vaccines in Pregnancy

Issues:

- Influenza vaccination recommended for pregnant persons
- While there is considerable experience with safe administration of influenza vaccines in pregnancy, there are fewer data specific to newer influenza vaccine formulations

Updates:

- ***Safety of Quadrivalent Recombinant Influenza Vaccine in Pregnant Women and their Infants—Dr. Nicky Klein (Kaiser Permanente Northern California)***
- ***Pregnancy Outcomes with cclIV4 (Flucelvax); Post Marketing Study—Dr. Gregg Sylvester (Seqirus)***
- ***Effectiveness of Maternal Influenza Vaccination during Pregnancy Against Influenza-associated Hospitalizations & ED Visits in Infants <6 Months of Age—Ms. Samantha Olson (CDC/NCIRD)***
 - *To be presented tomorrow*

Co-administration of Vaccines in Adults

Issues:

- Simultaneous administration or co-administration of all vaccines for which a recipient is due is a generally recommended practice for most combinations of vaccines
- Specific data for co-administration of many combinations involving newer vaccines are limited
- Data on co-administration of two or more vaccines with newer adjuvants are limited

Updates:

- ***Safety of Simultaneous versus Sequential Administration of mRNA COVID-19 and Quadrivalent Inactivated Influenza (IIV4) Vaccines***—Dr. Emmanuel “Chip” Walter (Duke University)
- ***Safety of Simultaneous Vaccination with Zoster Vaccine Recombinant (RZV) and Quadrivalent Adjuvanted Inactivated Influenza Vaccine (aIIV4)***—Dr. Kenneth Schmader (Duke University)
- ***Update on COVID-19 and Influenza Vaccine Safety***—Dr. Tom Shimabukuro (CDC/NCIRD)

Influenza B/Yamagata Surveillance

Issues:

- All current U.S. influenza vaccines are quadrivalent—they contain antigen from 4 influenza viruses, including an A(H1N1) virus, an A(H3N2) virus, and 2 influenza B viruses (one from each of two B lineages)
- Quadrivalent influenza vaccines were initially introduced in 2013-14, to permit broader coverage of potentially circulating influenza B viruses (previous trivalent vaccines contained one influenza B virus from one lineage)
- There have been no confirmed detections of influenza B/Yamagata lineage viruses in global surveillance since March 2020, leading to discussion by WHO and FDA of their continued inclusion in influenza vaccines

Update:

- ***Update on Influenza B/Yamagata Surveillance—Dr. Rebecca Kondor (CDC/NCIRD)***
 - *To be presented tomorrow*

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

